TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+3.64%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.91B
AUM Growth
+$2.91B
(+2.1%)
Cap. Flow
+$57.4M
Cap. Flow
% of AUM
1.98%
Top 10 Holdings %
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
49
Closed
30
Top Buys
| 1 |
Elevance Health
ELV
|
$45.8M |
| 2 |
Abbott
ABT
|
$37.5M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$31.8M |
| 4 |
Moderna
MRNA
|
$29.3M |
| 5 |
Gilead Sciences
GILD
|
$26.5M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$59.8M |
| 2 |
Becton Dickinson
BDX
|
$21.5M |
| 3 |
Humana
HUM
|
$19.1M |
| 4 |
Bio-Techne
TECH
|
$16.8M |
| 5 |
NovoCure
NVCR
|
$15.2M |
Sector Composition
| 1 | Healthcare | 95.75% |
| 2 | Real Estate | 2.99% |
| 3 | Industrials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $117M | 4.04% | 1,815,906 +410,535 | +29% | +$26.5M |
|
2
Amgen
AMGN
$155B
| $104M | 3.57% | 416,560 | – | – |
|
3
Johnson & Johnson
JNJ
$427B
| $99.4M | 3.42% | 604,864 +58,059 | +11% | +$9.54M |
|
4
Illumina
ILMN
$15.8B
| $94.8M | 3.26% | 246,793 -10,700 | -4% | -$4.11M |
|
|
5
Abbott
ABT
$231B
| $89.1M | 3.07% | 743,657 +312,512 | +72% | +$37.5M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $84.9M | 2.92% | 395,288 +89,978 | +29% | +$19.3M |
|
7
UnitedHealth
UNH
$281B
| $79M | 2.72% | 212,285 -6,900 | -3% | -$2.57M |
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $74.6M | 2.57% | 810,932 +345,916 | +74% | +$31.8M |
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $72.6M | 2.5% | 153,505 -25,880 | -14% | -$12.2M |
|
10
Biogen
BIIB
$19.4B
| $69.1M | 2.38% | 246,844 | – | – |
|
11
AbbVie
ABBV
$372B
| $67.1M | 2.31% | 619,759 | – | – |
|
|
12
Moderna
MRNA
$9.37B
| $61.8M | 2.13% | 472,302 +224,110 | +90% | +$29.3M |
|
|
13
Elevance Health
ELV
$71.8B
| $59.1M | 2.03% | 164,777 +127,644 | +344% | +$45.8M |
|
14
Medtronic
MDT
$119B
| $58.1M | 2% | 492,214 -42,700 | -8% | -$5.04M |
|
15
Bristol-Myers Squibb
BMY
$96B
| $56.3M | 1.94% | 892,453 -97,455 | -10% | -$6.15M |
|
16
Eli Lilly
LLY
$657B
| $54.6M | 1.88% | 292,114 +54,577 | +23% | +$10.2M |
|
17
Thermo Fisher Scientific
TMO
$186B
| $51.9M | 1.78% | 113,653 -13,900 | -11% | -$6.34M |
|
18
Cigna
CI
$80.3B
| $45.9M | 1.58% | 189,921 +54,209 | +40% | +$13.1M |
|
19
Danaher
DHR
$147B
| $43M | 1.48% | 191,240 -28,600 | -13% | -$6.44M |
|
20
Merck
MRK
$210B
| $41.8M | 1.44% | 541,703 -19,200 | -3% | -$1.48M |
|
21
Stryker
SYK
$150B
| $37M | 1.27% | 151,830 -1,500 | -1% | -$365K |
|
22
Zimmer Biomet
ZBH
$21B
| $33.3M | 1.14% | 207,814 -6,200 | -3% | -$993K |
|
|
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
| $31.3M | 1.08% | 225,490 -68,129 | -23% | -$9.46M |
|
24
Waters Corp
WAT
$18B
| $29.2M | 1% | 102,710 -6,800 | -6% | -$1.93M |
|
25
HCA Healthcare
HCA
$94.5B
| $28.8M | 0.99% | 152,897 -22,200 | -13% | -$4.18M |
|